JP2017516784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516784A5 JP2017516784A5 JP2016569606A JP2016569606A JP2017516784A5 JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5 JP 2016569606 A JP2016569606 A JP 2016569606A JP 2016569606 A JP2016569606 A JP 2016569606A JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- pharmaceutically acceptable
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003798P | 2014-05-28 | 2014-05-28 | |
| US62/003,798 | 2014-05-28 | ||
| US201462088200P | 2014-12-05 | 2014-12-05 | |
| US62/088,200 | 2014-12-05 | ||
| PCT/US2015/032990 WO2015184145A1 (en) | 2014-05-28 | 2015-05-28 | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516784A JP2017516784A (ja) | 2017-06-22 |
| JP2017516784A5 true JP2017516784A5 (enExample) | 2018-07-05 |
| JP6648040B2 JP6648040B2 (ja) | 2020-02-14 |
Family
ID=54699806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569606A Active JP6648040B2 (ja) | 2014-05-28 | 2015-05-28 | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10238630B2 (enExample) |
| EP (1) | EP3148336B1 (enExample) |
| JP (1) | JP6648040B2 (enExample) |
| WO (1) | WO2015184145A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| CN102369008B (zh) | 2009-03-30 | 2014-10-29 | 卫材R&D管理有限公司 | 脂质体组合物 |
| BR112015029386B1 (pt) | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
| ITUB20159206A1 (it) * | 2015-12-22 | 2017-06-22 | Olon Spa | Forme cristalline e amorfe di olaparib |
| WO2017188350A1 (ja) * | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| JP7025416B2 (ja) | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| CN110475475A (zh) * | 2017-02-06 | 2019-11-19 | 希望之城 | 癌症的治疗 |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| CN107098862A (zh) * | 2017-06-05 | 2017-08-29 | 山东裕欣药业有限公司 | 一种奥拉帕尼二水合物及其制备方法 |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN111918667A (zh) * | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| EP4552696A3 (en) * | 2018-05-15 | 2025-11-05 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| WO2020142583A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| WO2022217060A1 (en) * | 2021-04-09 | 2022-10-13 | Cardiff Oncology, Inc. | Cancer treatment using parp inhibitors and plk1 inhibitors |
| WO2024054898A1 (en) * | 2022-09-08 | 2024-03-14 | Cardiff Oncology, Inc. | Onvansertib and parp inhibitor combination |
| CA3267429A1 (en) | 2022-09-11 | 2024-03-14 | Cardiff Oncology, Inc. | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR THE TREATMENT OF METASTATIC CANCER |
| WO2024137738A1 (en) * | 2022-12-22 | 2024-06-27 | The Board Of Regents Of The University Of Oklahoma | Combinations of poly (adp-ribose) polymerase (parp) inhibitors and heteroarotinoids and methods of use as cancer treatments |
| CN121127241A (zh) * | 2023-03-10 | 2025-12-12 | 万春药业公司 | 肿瘤联合治疗及使用方法 |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| ES2504690T3 (es) * | 2007-10-03 | 2014-10-08 | Eisai Inc. | Compuestos inhibidores de PARP, composiciones y métodos de uso |
| EP2686441B1 (en) * | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| CA2843417C (en) * | 2011-07-29 | 2018-08-21 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
-
2015
- 2015-05-28 WO PCT/US2015/032990 patent/WO2015184145A1/en not_active Ceased
- 2015-05-28 US US15/314,200 patent/US10238630B2/en active Active
- 2015-05-28 EP EP15799685.1A patent/EP3148336B1/en active Active
- 2015-05-28 JP JP2016569606A patent/JP6648040B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516784A5 (enExample) | ||
| EP3148336B1 (en) | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| TWI361689B (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| TW200932239A (en) | PARP inhibitor compounds, compositions and methods of use | |
| EP3969050A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| ES2913097T3 (es) | Uso de derivados de quinolina para el tratamiento del cáncer de esófago y método de tratamiento, composición farmacéutica y equipo de los mismos | |
| KR20180129917A (ko) | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2013511526A5 (enExample) | ||
| Ali et al. | Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers | |
| JP2023505056A5 (enExample) | ||
| JP2019501962A5 (enExample) | ||
| CN101484443A (zh) | 放射线治疗增强剂 | |
| Goldman et al. | MA07. 05 phase 1b/2 study of combined HER inhibition in refractory EGFR-mutated metastatic non-small cell lung cancer (NSCLC) | |
| Han et al. | Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells | |
| Fecher et al. | Effectively targeting BRAF in melanoma: a formidable challenge. | |
| CN111777621B (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 | |
| CA3010654C (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| CN118019537A (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| TW202508573A (zh) | 用於治療癌症之組合療法 | |
| JP2024509269A5 (enExample) | ||
| WO2025250569A1 (en) | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors | |
| WO2025245463A9 (en) | Combination therapies | |
| TWI307628B (en) | Use of zd0473 in combination with a non-platinum based anti-cancer agent |